Enzon Pharmaceuticals CEO Jeffrey Buchalter's 2007 pay jumps 38% to $5.3M
Enzon Pharmaceuticals reports 2007 executive compensation
By ExecPay News
Published: April 16, 2008
Enzon Pharmaceuticals reported fiscal year 2007 executive compensation information on April 16, 2008.
In 2007, five executives at Enzon Pharmaceuticals received on average a compensation package of $2.2M, a 41% increase compared to previous year.
Average pay of disclosed executives at Enzon Pharmaceuticals
Jeffrey H. Buchalter, Chief Executive Officer, received $5.3M in total, which increased by 38% compared to 2006. 41% of Buchalter's compensation, or $2.1M, was in option awards. Buchalter also received $1.2M in non-equity incentive plan, $774K in salary, $975K in stock awards, as well as $208K in other compensation.
Ivan D. Horak, Chief Scientific Officer, received a compensation package of $1.8M, which increased by 41% compared to previous year. 38% of the compensation package, or $689K, was in option awards.
Craig A. Tooman, Chief Financial Officer, earned $1.7M in 2007, a 50% increase compared to previous year.
Ralph del Campo, Executive Vice President, Technical Operations, received $1.4M in 2007, which increases by 53% compared to 2006.
Paul S. Davit, Executive Vice President, Human Resources, earned $899K in 2007, a 22% increase compared to previous year.
Related executives
Ralph del Campo
Enzon Pharmaceuticals
Chief Operating Officer
Paul Davit
Enzon Pharmaceuticals
Executive Vice President, Human Resources and Administration
Jeffrey Buchalter
Enzon Pharmaceuticals
Chief Executive Officer
Craig Tooman
Enzon Pharmaceuticals
Chief Financial Officer
Ivan Horak
Enzon Pharmaceuticals
Chief Scientific Officer
You may also like
Source: SEC filing on April 16, 2008.